These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37204363)

  • 1. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
    Gregg LP; Ramsey DJ; Akeroyd JM; Jafry SA; Matheny ME; Virani SS; Navaneethan SD
    Am J Kidney Dis; 2023 Jul; 82(1):53-62.e1. PubMed ID: 36702340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
    Usman MS; Siddiqi TJ; Anker SD; Bakris GL; Bhatt DL; Filippatos G; Fonarow GC; Greene SJ; Januzzi JL; Khan MS; Kosiborod MN; McGuire DK; Piña IL; Rosenstock J; Vaduganathan M; Verma S; Zieroth S; Butler J
    J Am Coll Cardiol; 2023 Jun; 81(25):2377-2387. PubMed ID: 37344038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
    Bermudez SR; Anderson JR; Bos AJ; Ray GM
    Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
    Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
    Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.
    Wojcik C; Warden BA
    Curr Cardiol Rep; 2019 Sep; 21(10):130. PubMed ID: 31522263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review.
    Rahman H; Khan SU; Lone AN; Ghosh P; Kunduru M; Sharma S; Sattur S; Kaluski E
    J Am Heart Assoc; 2023 Aug; 12(16):e030578. PubMed ID: 37581396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
    Kovil R; Chawla M; Shah T; Sahoo A; Makkar B; Kesavadev J; Seshadri K; Tiwaskar M; Rajput R; Phatak S; Majumdar S; Gupta S
    J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
    Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
    Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C
    JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7.
    Mahtta D; Lee MT; Ramsey DJ; Akeroyd JM; Krittanawong C; Khan SU; Sinh P; Alam M; Garratt KN; Schofield RS; Ballantyne CM; Petersen LA; Virani SS
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):93-102. PubMed ID: 33400053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.